Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 21, 2014; 20(39): 14430-14441
Published online Oct 21, 2014. doi: 10.3748/wjg.v20.i39.14430
Published online Oct 21, 2014. doi: 10.3748/wjg.v20.i39.14430
FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation
Jun Yao, Chun-Suo Zhou, Bai-Qing Fu, Li-Sheng Tao, Ya-Ping Xu, Department of Gastroenterology, the People’s Hospital Affiliated to Jiangsu University, Zhenjiang 212002, Jiangsu Province, China
Xiong Ma, Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200127, China
Miao Chen, Department of Pathology, the Zhenjiang First People’s Hospital, Zhenjiang 212002, Jiangsu Province, China
Author contributions: Yao J and Zhou CS contributed equally to this study; Xu YP designed the research; Yao J, Zhou CS and Ma X performed the research; Tao LS and Fu BQ analyzed the data; Chen M performed the pathology research; Yao J wrote the paper.
Correspondence to: Ya-Ping Xu, Chief Physician, Department of Gastroenterology, the People’s Hospital Affiliated to Jiangsu University, 8 Dianli Road, Zhenjiang 212002, Jiangsu Province, China. yapingxu@yeah.net
Telephone: +86-511-88915641 Fax: +86-511-85234387
Received: January 9, 2014
Revised: March 6, 2014
Accepted: June 2, 2014
Published online: October 21, 2014
Processing time: 284 Days and 7.9 Hours
Revised: March 6, 2014
Accepted: June 2, 2014
Published online: October 21, 2014
Processing time: 284 Days and 7.9 Hours
Core Tip
Core tip: We found that the synthetic farnesoid X receptor (FXR) agonist GW4064 attenuated lipopolysaccharide-induced hepatic injury in high-fat diet-fed mice by reducing proinflammatory cytokine expression in macrophages. Moreover, we found that FXR expression was decreased in patients with nonalcoholic steatohepatitis, the most extreme form of nonalcoholic fatty liver disease (NAFLD), and was inversely correlated with the NAFLD activity score. Together, these findings provide insights into the etiology of NAFLD and suggest that FXR activation with synthetic agonists may represent a potential therapeutic option for patients with NAFLD, which we believe will be of great interest to the readers of the journal.